BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35931701)

  • 1. AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling.
    Ferrarotto R; Mishra V; Herz E; Yaacov A; Solomon O; Rauch R; Mondshine A; Motin M; Leibovich-Rivkin T; Davis M; Kaye J; Weber CR; Shen L; Pearson AT; Rosenberg AJ; Chen X; Singh A; Aster JC; Agrawal N; Izumchenko E
    Cell Death Dis; 2022 Aug; 13(8):678. PubMed ID: 35931701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
    Ferrarotto R; Mitani Y; Diao L; Guijarro I; Wang J; Zweidler-McKay P; Bell D; William WN; Glisson BS; Wick MJ; Kapoun AM; Patnaik A; Eckhardt G; Munster P; Faoro L; Dupont J; Lee JJ; Futreal A; El-Naggar AK; Heymach JV
    J Clin Oncol; 2017 Jan; 35(3):352-360. PubMed ID: 27870570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.
    Stoeck A; Lejnine S; Truong A; Pan L; Wang H; Zang C; Yuan J; Ware C; MacLean J; Garrett-Engele PW; Kluk M; Laskey J; Haines BB; Moskaluk C; Zawel L; Fawell S; Gilliland G; Zhang T; Kremer BE; Knoechel B; Bernstein BE; Pear WS; Liu XS; Aster JC; Sathyanarayanan S
    Cancer Discov; 2014 Oct; 4(10):1154-67. PubMed ID: 25104330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of the Gamma Secretase Inhibitor AL101 in Desmoid Tumors: A Case Report of 2 Adult Cases.
    Chan D; Kaplan J; Gordon G; Desai J
    Curr Oncol; 2021 Sep; 28(5):3659-3667. PubMed ID: 34590610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical disease course and survival outcomes following disease recurrence in adenoid cystic carcinoma with and without NOTCH signaling pathway activation.
    Feeney L; Hapuarachi B; Adderley H; Rack S; Morgan D; Walker R; Rauch R; Herz E; Kaye J; Harrington K; Metcalf R
    Oral Oncol; 2022 Oct; 133():106028. PubMed ID: 35952580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lentiviral-mediated gene silencing of Notch-4 inhibits in vitro proliferation and perineural invasion of ACC-M cells.
    Chen W; Zhang H; Wang J; Cao G; Dong Z; Su H; Zhou X; Zhang S
    Oncol Rep; 2013 May; 29(5):1797-804. PubMed ID: 23450325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Notch Inhibitor Shows Modest Efficacy.
    Cancer Discov; 2017 Feb; 7(2):OF3. PubMed ID: 27974417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.
    Hanna GJ; Stathis A; Lopez-Miranda E; Racca F; Quon D; Leyvraz S; Hess D; Keam B; Rodon J; Ahn MJ; Kim HR; Schneeweiss A; Ribera JM; DeAngelo D; Perez Garcia JM; Cortes J; Schönborn-Kellenberger O; Weber D; Pisa P; Bauer M; Beni L; Bobadilla M; Lehal R; Vigolo M; Vogl FD; Garralda E
    Cancer Res Commun; 2023 Sep; 3(9):1853-1861. PubMed ID: 37712875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations of Notch pathway in patients with adenoid cystic carcinoma of the trachea and its impact on survival.
    Xie M; Wei S; Wu X; Li X; You Y; He C
    Lung Cancer; 2018 Jul; 121():41-47. PubMed ID: 29858025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Notch-4 contributes to the metastasis of salivary adenoid cystic carcinoma.
    Ding LC; She L; Zheng DL; Huang QL; Wang JF; Zheng FF; Lu YG
    Oncol Rep; 2010 Aug; 24(2):363-8. PubMed ID: 20596622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem-Like Cells in Adenoid Cystic Carcinoma.
    Panaccione A; Chang MT; Carbone BE; Guo Y; Moskaluk CA; Virk RK; Chiriboga L; Prasad ML; Judson B; Mehra S; Yarbrough WG; Ivanov SV
    Clin Cancer Res; 2016 Apr; 22(8):2083-95. PubMed ID: 27084744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic Adenoid Cystic Carcinoma: Genomic Landscape and Emerging Treatments.
    de Sousa LG; Jovanovic K; Ferrarotto R
    Curr Treat Options Oncol; 2022 Aug; 23(8):1135-1150. PubMed ID: 35854180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rethinking Gamma-secretase Inhibitors for Treatment of Non-small-Cell Lung Cancer: Is Notch the Target?
    Pine SR
    Clin Cancer Res; 2018 Dec; 24(24):6136-6141. PubMed ID: 30104200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of PDX-derived salivary adenoid cystic carcinoma cell lines using organoid culture method.
    Takada K; Aizawa Y; Sano D; Okuda R; Sekine K; Ueno Y; Yamanaka S; Aoyama J; Sato K; Kuwahara T; Hatano T; Takahashi H; Arai Y; Nishimura G; Taniguchi H; Oridate N
    Int J Cancer; 2021 Jan; 148(1):193-202. PubMed ID: 32984947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
    Wong SJ; Karrison T; Hayes DN; Kies MS; Cullen KJ; Tanvetyanon T; Argiris A; Takebe N; Lim D; Saba NF; Worden FP; Gilbert J; Lenz HJ; Razak AR; Roberts JD; Vokes EE; Cohen EE
    Ann Oncol; 2016 Feb; 27(2):318-23. PubMed ID: 26598548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solid-type adenoid cystic carcinoma of the breast, a distinct molecular entity enriched in NOTCH and CREBBP mutations.
    Massé J; Truntzer C; Boidot R; Khalifa E; Pérot G; Velasco V; Mayeur L; Billerey-Larmonier C; Blanchard L; Charitansky H; Soubeyran I; Iggo R; Arnould L; MacGrogan G
    Mod Pathol; 2020 Jun; 33(6):1041-1055. PubMed ID: 31857685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
    Agulnik M; Cohen EW; Cohen RB; Chen EX; Vokes EE; Hotte SJ; Winquist E; Laurie S; Hayes DN; Dancey JE; Brown S; Pond GR; Lorimer I; Daneshmand M; Ho J; Tsao MS; Siu LL
    J Clin Oncol; 2007 Sep; 25(25):3978-84. PubMed ID: 17761983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.
    Konishi J; Kawaguchi KS; Vo H; Haruki N; Gonzalez A; Carbone DP; Dang TP
    Cancer Res; 2007 Sep; 67(17):8051-7. PubMed ID: 17804716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BH3-mimetic small molecule inhibits the growth and recurrence of adenoid cystic carcinoma.
    Acasigua GA; Warner KA; Nör F; Helman J; Pearson AT; Fossati AC; Wang S; Nör JE
    Oral Oncol; 2015 Sep; 51(9):839-47. PubMed ID: 26121939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.